3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Withdrawn
1
Sponsor Class
OTHER_GOV
1
Study Type
Interventional
1
Sponsor
Conditions
Opportunistic Infections
1
Inflammation
1
Epstein-Barr Virus Infections
1
Cytomegalovirus Infections
1
Coinfection
1
Acquired Immunodeficiency Syndrome
1
Interventions
Ritonavir
2
Human Papillomavirus Recombinant Vaccine nonavalent
2
dolutegravir
1
Papillomavirus Vaccines
1
Nucleosides
1
Nevirapine
1
Lopinavir
1
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
1
Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination
1
Emtricitabine
1
Darunavir
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 4
×
Acquired Immunodeficiency Syndrome
×
dolutegravir
×
Clear all
NCT04183738
2020-11-10
i2-D²EFT
Kirby Institute
Phase 4
Withdrawn